Vigil Neuroscience (NASDAQ:VIGL) Receives Buy Rating from HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $24.00 price target on the stock.

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, April 18th.

Vigil Neuroscience Price Performance

NASDAQ:VIGL opened at $3.19 on Wednesday. The company has a market cap of $119.89 million, a price-to-earnings ratio of -1.50 and a beta of 1.87. Vigil Neuroscience has a 1 year low of $2.50 and a 1 year high of $11.11. The stock’s 50 day simple moving average is $3.07 and its two-hundred day simple moving average is $3.74.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.01). As a group, analysts anticipate that Vigil Neuroscience will post -2.56 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio purchased a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,200 shares of the company’s stock, valued at approximately $27,000. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.